Tselis A - Search Results

1

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.

Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O. Memon AB, et al. Among authors: tselis a. PLoS One. 2018 Jan 8;13(1):e0190425. doi: 10.1371/journal.pone.0190425. eCollection 2018. PLoS One. 2018. PMID: 29309416 Free PMC article.

2

Non-lyme tick-borne diseases: a neurological perspective.

Seraji-Bozorgzad N, Tselis AC. Seraji-Bozorgzad N, et al. Curr Neurol Neurosci Rep. 2013 Oct;13(10):388. doi: 10.1007/s11910-013-0388-6. Curr Neurol Neurosci Rep. 2013. PMID: 24014177 Review.

3

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.

Khan O, Shen Y, Bao F, Caon C, Tselis A, Latif Z, Zak I. Khan O, et al. Among authors: tselis a. J Neuroimaging. 2008 Jul;18(3):314-9. doi: 10.1111/j.1552-6569.2007.00206.x. J Neuroimaging. 2008. PMID: 18304034

4

Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

Khan O, Bao F, Shah M, Caon C, Tselis A, Bailey R, Silverman B, Zak I. Khan O, et al. Among authors: tselis a. J Neurol Sci. 2012 Jan 15;312(1-2):7-12. doi: 10.1016/j.jns.2011.08.034. Epub 2011 Sep 13. J Neurol Sci. 2012. PMID: 21920559

5

Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.

Bernitsas E, Bao F, Seraji-Bozorgzad N, Chorostecki J, Santiago C, Tselis A, Caon C, Zak I, Millis S, Khan O. Bernitsas E, et al. Among authors: tselis a. Mult Scler Relat Disord. 2015 Jan;4(1):47-51. doi: 10.1016/j.msard.2014.11.002. Epub 2014 Nov 18. Mult Scler Relat Disord. 2015. PMID: 25787052

6

Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis.

Seraji-Bozorgzad N, Khan O, Cree BAC, Bao F, Caon C, Zak I, Razmjou S, Tselis A, Millis S, Bernitsas E. Seraji-Bozorgzad N, et al. Among authors: tselis a. J Neuroimaging. 2017 Sep;27(5):476-480. doi: 10.1111/jon.12435. Epub 2017 Mar 29. J Neuroimaging. 2017. PMID: 28371088

7

Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.

Bernitsas E, Khan O, Razmjou S, Tselis A, Bao F, Caon C, Millis S, Seraji-Bozorgzad N. Bernitsas E, et al. Among authors: tselis a. PLoS One. 2017 Jul 20;12(7):e0181431. doi: 10.1371/journal.pone.0181431. eCollection 2017. PLoS One. 2017. PMID: 28727770 Free PMC article.

8

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R. Khan O, et al. Among authors: tselis a. CNS Drugs. 2002;16(8):563-78. doi: 10.2165/00023210-200216080-00005. CNS Drugs. 2002. PMID: 12096936 Review.

9

Acute transverse myelitis with normal brain MRI : long-term risk of MS.

Perumal J, Zabad R, Caon C, MacKenzie M, Tselis A, Bao F, Latif Z, Zak I, Lisak R, Khan O. Perumal J, et al. Among authors: tselis a. J Neurol. 2008 Jan;255(1):89-93. doi: 10.1007/s00415-007-0686-5. Epub 2007 Dec 20. J Neurol. 2008. PMID: 18080852

10

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O; Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine. Boster A, et al. Among authors: tselis a. Lancet Neurol. 2008 Feb;7(2):173-83. doi: 10.1016/S1474-4422(08)70020-6. Lancet Neurol. 2008. PMID: 18207115 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page